Payment overview · 2025
General Payments
$714.92
32 reported records · 15 companies
Healthcare provider profile · identity verified
Aleksandr Orlovskiy, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1457501447
Verified facts
What the public records show
CMS Open Payments records show Aleksandr Orlovskiy, MD received $714.92 in general payments during 2025 across 32 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Gemtesa, Linzess, Otezla, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 316 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 258 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Lokelma by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 729 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.32 | 19.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $94.36 | 13.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.03 | 9.5% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$66.35 | 9.3% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $64.53 | 9.0% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $51.06 | 7.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.44 | 6.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.18 | 3.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.86 | 3.8% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $25.38 | 3.5% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $24.00 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.64 | 3.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $20.00 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.12 | 2.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.65 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $714.92 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $102.44 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $94.36 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $68.03 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $68.03 | 3 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $64.53 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $51.06 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| CG FUTURE Normalized: cg future |
Device | Medtronic, Inc. | $38.33 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.88 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $36.86 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $33.13 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.50 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.86 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $25.38 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.12 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 316 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 729 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 43 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 310 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
316 | 73 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
310 | 64 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
258 | 38 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
178 | 39 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
54 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
729 | 271 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1006 | 359 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 948 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 941 | 280 |
| Metoprolol Succinate | Metoprolol Succinate | 795 | 242 |
| Eliquis | Apixaban | 729 | 271 |
| Losartan Potassium | Losartan Potassium | 664 | 213 |
| Metoprolol Tartrate | Metoprolol Tartrate | 620 | 212 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 194 |
| Omeprazole | Omeprazole | 574 | 158 |
| Tamsulosin Hcl | Tamsulosin Hcl | 566 | 200 |
| Gabapentin | Gabapentin | 522 | 184 |
| Pantoprazole Sodium | Pantoprazole Sodium | 518 | 238 |
| Furosemide | Furosemide | 515 | 196 |
| Diclofenac Sodium | Diclofenac Sodium | 448 | 95 |
| Metformin Hcl | Metformin Hcl | 421 | 119 |
| Vascepa | Icosapent Ethyl | 392 | 70 |
| Carvedilol | Carvedilol | 374 | 111 |
| Clopidogrel | Clopidogrel Bisulfate | 373 | 104 |
| Escitalopram Oxalate | Escitalopram Oxalate | 369 | 104 |
| Famotidine | Famotidine | 335 | 131 |
| Hydralazine Hcl | Hydralazine Hcl | 320 | 102 |
| Creon | Lipase/Protease/Amylase | 316 | 73 |
| Linzess | Linaclotide | 310 | 64 |
| Dexlansoprazole Dr | Dexlansoprazole | 286 | 45 |
| Meloxicam | Meloxicam | 277 | 70 |
| Synthroid | Levothyroxine Sodium | 258 | 38 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 257 | 49 |
| Citalopram Hbr | Citalopram Hydrobromide | 252 | 85 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 224 | 51 |
| Lorazepam | Lorazepam | 207 | 53 |
| Lisinopril | Lisinopril | 203 | 58 |
| Clonidine Hcl | Clonidine Hcl | 202 | 45 |
| Memantine Hcl | Memantine Hcl | 201 | 91 |
| Finasteride | Finasteride | 200 | 64 |
| Meclizine Hcl | Meclizine Hcl | 195 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 42 |
| Jardiance | Empagliflozin | 185 | 44 |
| Simvastatin | Simvastatin | 185 | 55 |
| Santyl | Collagenase Clostridium Hist. | 182 | 59 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 181 | 73 |
| Zenpep | Lipase/Protease/Amylase | 178 | 39 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 177 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 165 | 43 |
| Trazodone Hcl | Trazodone Hcl | 165 | 60 |
| Entresto | Sacubitril/Valsartan | 162 | 47 |
| Sertraline Hcl | Sertraline Hcl | 162 | 53 |
| Donepezil Hcl | Donepezil Hcl | 154 | 70 |
| Icosapent Ethyl | Icosapent Ethyl | 151 | 43 |
| Nifedipine Er | Nifedipine | 151 | 53 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 150 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 46 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 148 | 30 |
| Memantine Hcl Er | Memantine Hcl | 147 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 147 | 41 |
| Allopurinol | Allopurinol | 145 | 53 |
| Myrbetriq | Mirabegron | 145 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 59 |
| Dutasteride | Dutasteride | 143 | 29 |
| Divalproex Sodium | Divalproex Sodium | 141 | 42 |
| Mirtazapine | Mirtazapine | 139 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 52 |
| Sodium Chloride | 0.9 % Sodium Chloride | 129 | 42 |
| Xarelto | Rivaroxaban | 123 | 37 |
| Labetalol Hcl | Labetalol Hcl | 122 | 43 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 120 | 29 |
| Tramadol Hcl | Tramadol Hcl | 120 | 42 |
| Lactulose | Lactulose | 119 | 59 |
| Levofloxacin | Levofloxacin | 119 | 95 |
| Celecoxib | Celecoxib | 117 | 35 |
| Potassium Chloride | Potassium Chloride | 116 | 53 |
| Ammonium Lactate | Ammonium Lactate | 114 | 54 |
| Januvia | Sitagliptin Phosphate | 114 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 111 | 36 |
| Ezetimibe | Ezetimibe | 111 | 36 |
| Levetiracetam | Levetiracetam | 111 | 38 |
| Dexilant | Dexlansoprazole | 110 | 16 |
| Enalapril Maleate | Enalapril Maleate | 109 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 108 | 20 |
| Hydrocortisone | Hydrocortisone | 105 | 41 |
| Atenolol | Atenolol | 102 | 26 |
| Nitroglycerin | Nitroglycerin | 100 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 98 | 45 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 73 |
| Mupirocin | Mupirocin | 96 | 40 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 96 | 35 |
| Azithromycin | Azithromycin | 95 | 79 |
| Alendronate Sodium | Alendronate Sodium | 93 | 31 |
| Clonazepam | Clonazepam | 93 | 27 |
| Ketoconazole | Ketoconazole | 92 | 49 |
| Olanzapine | Olanzapine | 92 | 23 |
| Valsartan | Valsartan | 92 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 92 | 31 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 87 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 84 | 14 |
| Latanoprost | Latanoprost | 83 | 49 |
| Glimepiride | Glimepiride | 82 | 20 |
| Tradjenta | Linagliptin | 82 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 31 |
| Admelog Solostar | Insulin Lispro | 78 | 53 |
| Farxiga | Dapagliflozin Propanediol | 78 | 23 |
| Montelukast Sodium | Montelukast Sodium | 77 | 31 |
| Buspirone Hcl | Buspirone Hcl | 76 | 24 |
| Ranolazine Er | Ranolazine | 76 | 23 |
| Glipizide | Glipizide | 75 | 22 |
| Spironolactone | Spironolactone | 74 | 30 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 73 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 73 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 73 | 15 |
| Nystatin | Nystatin | 71 | 31 |
| Prednisone | Prednisone | 71 | 36 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 69 | 50 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 15 |
| Methimazole | Methimazole | 67 | 23 |
| Loperamide | Loperamide Hcl | 66 | 23 |
| Clotrimazole | Clotrimazole | 65 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 16 |
| Metformin Hcl Er | Metformin Hcl | 64 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 37 |
| Glipizide Er | Glipizide | 63 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 62 | 28 |
| Trulicity | Dulaglutide | 62 | 14 |
| Ibuprofen | Ibuprofen | 61 | 33 |
| Ozempic | Semaglutide | 61 | 12 |
| Calcitriol | Calcitriol | 60 | 16 |
| Torsemide | Torsemide | 60 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | 24 |
| Edarbi | Azilsartan Medoxomil | 59 | suppressed |
| Lidocaine | Lidocaine | 59 | 17 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 56 | 19 |
| Procto-Med Hc | Hydrocortisone | 56 | suppressed |
| Risperidone | Risperidone | 56 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 15 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 55 | 22 |
| Cilostazol | Cilostazol | 54 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 54 | 28 |
| Alcohol Pads | Alcohol Antiseptic Pads | 53 | 12 |
| Digoxin | Digoxin | 51 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 38 |
| Valacyclovir | Valacyclovir Hcl | 51 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 50 | suppressed |
| Clonidine | Clonidine | 49 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 49 | 14 |
| Midodrine Hcl | Midodrine Hcl | 49 | 28 |
| Rexulti | Brexpiprazole | 48 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 48 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 47 | 23 |
| Colchicine | Colchicine | 46 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 45 | 12 |
| Irbesartan | Irbesartan | 44 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 44 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 44 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | 18 |
| Gemtesa | Vibegron | 43 | 12 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 17 |
| Alprazolam | Alprazolam | 42 | 15 |
| Proctozone-Hc | Hydrocortisone | 42 | 11 |
| Silodosin | Silodosin | 42 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 41 | 11 |
| Crestor | Rosuvastatin Calcium | 41 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 40 | 22 |
| Febuxostat | Febuxostat | 39 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 39 | suppressed |
| Amantadine | Amantadine Hcl | 38 | 13 |
| Azelastine Hcl | Azelastine Hcl | 38 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 38 | 20 |
| Nystop | Nystatin | 38 | 19 |
| Silver Sulfadiazine | Silver Sulfadiazine | 38 | 16 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 15 |
| Cephalexin | Cephalexin | 37 | 29 |
| Nitroglycerin Patch | Nitroglycerin | 37 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 37 | 16 |
| Ssd | Silver Sulfadiazine | 36 | 16 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 15 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Baclofen | Baclofen | 32 | 16 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 31 | 17 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 25 |
| Erythromycin | Erythromycin Base | 30 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | 19 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 29 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 29 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Trulance | Plecanatide | 27 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | 13 |
| Acyclovir | Acyclovir | 25 | 13 |
| Meloxicam | Meloxicam, Submicronized | 25 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | 11 |
| Metronidazole | Metronidazole | 24 | 11 |
| Pentasa | Mesalamine | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 21 |
| Metformin Er Osmotic | Metformin Hcl | 23 | suppressed |
| Mupirocin | Mupirocin Calcium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 21 |
| Bumetanide | Bumetanide | 22 | 18 |
| Calcium Acetate | Calcium Acetate | 22 | 16 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 22 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | 12 |
| Enulose | Lactulose | 22 | 20 |
| Pitavastatin Calcium | Pitavastatin Calcium | 22 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Ertapenem | Ertapenem Sodium | 21 | suppressed |
| Ibuprofen-Famotidine | Ibuprofen/Famotidine | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 21 | suppressed |
| Alogliptin | Alogliptin Benzoate | 20 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 20 | 15 |
| Restasis | Cyclosporine | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Levocarnitine | Levocarnitine | 19 | suppressed |
| Livalo | Pitavastatin Calcium | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 18 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 18 | suppressed |
| Eplerenone | Eplerenone | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Daptomycin | Daptomycin | 17 | suppressed |
| Fluocinonide | Fluocinonide | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | 14 |
| Otezla | Apremilast | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Eysuvis | Loteprednol Etabonate | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Timolol Maleate | Timolol Maleate | 15 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 14 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 14 | suppressed |
| Exemestane | Exemestane | 14 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 14 | suppressed |
| Meropenem | Meropenem | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Vesicare | Solifenacin Succinate | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 13 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Vancomycin Hcl-0.9% Nacl | Vancomycin/0.9 % Sod Chloride | 13 | suppressed |
| Ztlido | Lidocaine | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Cyclosporine | Cyclosporine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 11 | suppressed |
| Benicar | Olmesartan Medoxomil | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $714.92 · 32 records | ABBVIE INC. | AMVUTTRA, CG FUTURE, CREON, ELIQUIS, FARXIGA, GEMTESA, IBSRELA, LINZESS, NURTEC ODT, OTEZLA, Ozempic, PERCEPT PC BRAINSENSE, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOWST, XIFAXAN, YUPELRI, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error